Close
FINDING CURES TOGETHER<sup>SM</sup>

Program

Daily Schedule - Wednesday - September 16

Welcome  
1:30 p.m.-1:35 p.m.

Jill O’Donnell-Tormey, Cancer Research Institute, New York, New York

Keynote Address
1:35 p.m.-2:05 p.m.

T cells as a drug for the personalized immunotherapy of cancer
Steven A. Rosenberg, National Cancer Institute, Bethesda, Maryland


Plenary Session 1: Immune Regulation of T Cell Responses / Evolving Concepts in Cancer Immunology
Session Chairperson: James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas
2:05 p.m.-4:05 p.m.

Chairperson perspective
Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for a cure
James P. Allison

Biology of the PD-1 pathway
Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts

Anti-tumor activity of immunomodulatory antibodies
Alan Korman, Bristol-Myers Squibb, Redwood City, California

The interplay between L-arginine metabolism and adoptive immunity in cancer
Vincenzo Bronte, Venetian Institute of Molecular Medicine, Padova, Italy

Tumor-derived CD103+ dendritic cells carry antigen to the tumor-draining lymph node and are essential for CD8+ T cell priming*
Edward Roberts, University of California, San Francisco, California


Refreshment Break
4:05 p.m.-4:35 p.m.


Plenary Session 2: Tumor Antigens for Targeting: Insights from Genomics
Session Chairperson: Christoph Huber, Johannes Gutenberg University Mainz Medical Center, Mainz, Germany
4:35 p.m.-6:35 p.m.

Chairperson perspective
Christoph Huber

Personalizing cancer immunotherapy
Robert D. Schreiber, Washington University School of Medicine, St. Louis, Missouri 

Targeting the mutanome for individualized cancer immunotherapy
Ugur Sahin, TRON Translational Cancer Center-Johannes Gutenberg University; BioNTech Biopharmaceutical New Technologies Corporation, Mainz, Germany

Impact of the immunogenic landscape of cancers on immunotherapy
Hans-Georg Rammensee, University of Tuebingen, Tuebingen, Germany

Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens*
Todd D. Prickett, National Cancer Institute, Bethesda, Maryland


Poster Session A
6:45 p.m.-8:45 p.m.


*Short talks from proffered abstracts

#cicon15

Top of page